T cells are known to regulate the migration of macro phages; helper T cells produce macrophage migration in hibition factor (MIF), while another subpopulation of T cells produces macrophage migration enhancement factor (MEF), and both functions are mutually exclusive in cell mediated immunity. MIF was first identified as a lym phokine that inhibits the migration of macrophages in vitro (1) . MIF is known to be involved in delayed-type hypersensitivity, cellular immunity and the sustained localization of macrophages at the site of inflammation (1) (2) (3) (4) (5) . On the other hand, MEF is produced after ad ministering a desensitizing dose of purified derivative (PPD) to Mycobacterium bovis BCG-sensitized rabbits (6, 7) . The mixture of MIF and MEF resulted in the mutual neutralization of each activity (7, 8) . The monosaccharides L-fucose, D-mannose, L-galactose, and their BSA conjugates were also shown to neutralize MIF activity and have potential to stimulate alveolar macro phage (AM) migration by themselves (8, 9) . We speculat ed that compounds with MEF activity might induce the dispersion of infiltrated macrophages from the inflamma tory sites and thereby exhibit anti-inflammatory activity.
TA-383 cis-2-(4-chlorophenyl)-4, 5-diphenyl-2-imid azoline hydrochloride has been developed as a new anti rheumatic drug with immunomodulatory activities (10). TA-383 inhibited the production of interleukin 1 (IL-1) (11) and interleukin 6 (IL-6) (12). TA-383 showed potent inhibitory effects on the delayed type hypersensitivity (DTH) reaction against the component of Mycobacteri um tuberculosis in rabbits and type II collagen (CII)-in duced arthritis in mice. In the present study, we investi gated the effects of TA-383 on macrophage migration activity and the production and/or release of MEF-like factors from spleen cells of normal rabbits.
TA-383, lobenzarit disodium (CCA), bucillamine (SA 96) and salazosulfapyridine (SASP) were synthesized in our laboratory. Dexamethasone (DM; Sigma Chemical Co., St. Louis, MO, USA), picryl chloride (PC; Tokyo Kasei, Tokyo), olive oil, bovine CII (Koken, Tokyo), complete Freund's adjuvant (FCA; Difco Laboratories, Detroit, MI, USA) were used.
The activity of macrophage migration was measured as follows: AM were obtained from rabbits by pulmonary lavage with 0.9% saline as described by McGee and Myrvik (13) . The cells were washed twice with RPMI 1640 and checked for viability. Direct assay: The capillary tube migration assay method (7) was used. AM were suspended in standard medium (RPMI-1640 plus 10% normal rabbit serum, 100 U/ml penicillin, 100 pg/ml streptomycin and 40 mM HEPES (pH 7.4)), loaded into the capillaries, and centrifuged at 55 x g for 10 min to sediment AM. The capillary was cut into 3.5-mm lengths and mounted in the chambers. The chambers were sealed with wax, and then standard medium or test medium was added to the chambers. The sealed chambers were incubated for 24 hr at 371C. Migrations were quantitated by tracing the area of migrated macrophages at tenfold magnification and calculated by the following formula: ° control migration = (area of enhanced migration / area of normal migration) x 100. Indirect assay: Spleen cells (2 x 107 cells/ml) from normal rabbits were suspended in standard medium containing drugs and incubated for 48 hr at 371C. Supernatants were collected by centrifugation (300 x g, 10 min) and then tested by the direct assay.
PC-DTH: Female BALB/c mice (10-weeks-old; Charles River Japan, Inc., Atsugi) were painted on shaved abdominal skin with 100 p1 of 7% PC in ethanol. After the 7-day sensitization period, mice were challenged by painting 14 pl of 1 ° PC in olive oil on the inside of the right ear. The thickness of the ear was measured at 24 hr after the PC challenge. TA-383 was administered orally once a day from day 0 to day 7 after sensitization.
CII-induced arthritis: DBA/ 1 J mice (7-weeks-old, fe male; Charles River Japan, Inc.) received an emulsion of 100 pg bovine CII in an equal volume of FCA at the base of the tail. On day 7, a second booster dose was given by the same route. The negative control group received equivalent amounts of 0.05 M acetic acid in FCA on days 0 and 7. TA-383, CCA and DM were administered orally for 12 weeks (5 days a week) from the day of first im munization. The arthritic score and the immune-mediated acute inflammatory response were measured at 12 weeks from the first immunization. The arthritic lesions on each limb of each animals was scored on a scale from 0 to 2 (0 = no arthritis , 1 = one arthritic joint, 2 = two or more arthritic joints and/or edema on entire paw). The score of each paw was added to give a maximal attainable score of 8 for each mouse. At one day before sacrifice, 10,ug of bovine CII in phosphate-buffered saline (pH 7.4) was in jected in the right ear, and the thickness of the ear was measured at 24 hr after the bovine CII challenge. (Fig. 1) . Furthermore, TA-383 (10-9 M) increased MEF-like activity by twofold when compared to control normal rabbit spleen cells (indirect method). This activity slightly changed when we removed TA-383 by dialysis (data not shown).
The effect of TA-383 on the mouse PC-DTH reaction is show in Table 1 . TA-383 was administered orally once a day for 7 consecutive days from the day of sensitization with PC. TA-383 significantly suppressed the PC-DTH reaction at a dose of 0.4 mg/kg at a percent inhibition of 88%. Body weight gain was not affected by TA-383 (data not shown). Table 2 shows the results of CII-induced arthritis in DBA/ 1 J mice. As described in our report, the arthritis score increased gradually from 5 to 10 weeks after the first immunization and reached a plateau thereafter (14) . DM at a dose of 0.25 mg/kg and TA-383 at a dose of 0.4 mg/kg significantly reduced the arthritis score, and the percentages of inhibition were 90% and 82°Io, respec tivity. On the other hand, CCA only slightly reduced the arthritis score. This suggests a close correlation between the arthritis score and the PC-DTH reaction. The dose effect relationship in the present study of TA-383 is, therefore, considered to show a bell-shaped pattern, which occurs in the dose-effects of immunomodulators (15) . TA-383 has the immunomodulatory activity of lowering the elevated antibody-producing responses in colchicine-treated mice and normalizing the depressed antibody-producing responses in mice loaded with water immersion stress (10) .
The ear swelling of mice after injection of bovine CII is known to develop through the activation of cellular immunity and humoral immunity. This immune-mediated acute inflammatory response was suppressed by DM at a dose of 0.25 mg/kg and TA-383 at a dose of 0.4 mg/kg ( Table 2) .
In this study, we demonstrated that TA-383 stimulated rabbit alveolar macrophage migration and enhanced the production and/or release of MEF-like factor by rabbit spleen cells at nanomolar concentration. TA-383 might be able to inhibit MIF activity through the induction of MEF because MEF can block the activity of MIF (8, 9) , However, the possible role of MEF in a cell-mediated im mune response is unclear. MIF activity was reported to be associated with DTH (1, 2), the enhancement of macro phage adherence and phagocytosis, and up-regulation of genes encoding human leucocyte antigen (HLA)-DR and IL-1 (5). Furthermore, TA-383 can inhibit IL-1 produc tion by human peripheral blood monocytes and synovial cells (11) . These results suggest that the anti-rheumatic activity of TA-383 may be exerted through the modifica tion of macrophage function such as migration activity. Mice were immunized with CII in complete Freund's adjuvant at the base of the tail on day 0 and day 7. The test compounds were ad ministered orally for 12 weeks. After 12 weeks from the first im munization, the arthritis score and the immune-mediated acute inflammatory response (DTH reaction) were measured. Each value represents the mean±S.E. of 8 animals. t: Significantly different from the control at P<0.01, Dunnett's method.
